State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)

State Street Corp increased its stake in shares of Rezolute, Inc. (NASDAQ:RZLT) by 11.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,472 shares of the company’s stock after buying an additional 13,000 shares during the period. State Street Corp owned 0.22% of Rezolute worth $609,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Jeppson Wealth Management LLC acquired a new stake in shares of Rezolute in the 2nd quarter valued at $45,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Rezolute in the third quarter worth about $65,000. XTX Topco Ltd raised its holdings in Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after purchasing an additional 42,597 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Rezolute during the 3rd quarter valued at about $239,000. Institutional investors own 82.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on RZLT. BTIG Research boosted their price target on shares of Rezolute from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a research report on Friday, September 20th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Friday, November 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $112.00 price objective on shares of Rezolute in a research note on Monday, November 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Rezolute presently has a consensus rating of “Buy” and an average target price of $24.13.

Insider Buying and Selling at Rezolute

In other Rezolute news, CFO Daron Evans bought 9,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $4.60 per share, with a total value of $41,400.00. Following the purchase, the chief financial officer now owns 140,900 shares in the company, valued at $648,140. This trade represents a 6.82 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 18.39% of the company’s stock.

Rezolute Stock Up 1.7 %

RZLT opened at $5.24 on Friday. The stock has a market cap of $303.62 million, a P/E ratio of -4.13 and a beta of 1.01. Rezolute, Inc. has a 12 month low of $0.90 and a 12 month high of $6.19. The company has a fifty day simple moving average of $5.08 and a 200 day simple moving average of $4.75.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.